Live Breaking News & Updates on Of azn gb0009895292
Stay updated with breaking news from Of azn gb0009895292. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
British finance minister Jeremy Hunt took aim at the economic plans of former prime minister Liz Truss on Wednesday, saying they had shown why tax cuts should not be funded out of increased. | March 29, 2023 ....
A safety panel of the European drug regulator on Friday recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca s COVID-19 vaccine.. | January 14, 2022 ....
LONDON — AstraZeneca, the drugmaker that developed one of the first COVID-19 vaccines, has asked the U.S. Food and Drug Administration to authorize the emergency use of a first-of-a-kind. | October 5, 2021 ....
Message : Required fields NEW DELHI/NEW YORK (Reuters) - Pfizer and the Indian government are seeking to resolve tensions over a demand by the U.S. drugmaker for legal protection from any claims linked to the use of its COVID-19 vaccine in one of the world s biggest markets, two sources told Reuters. India has not given any manufacturer of a COVID-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely used, including Britain and the United States. But three other sources told Reuters that some form of legal protection is still on the table as India and Pfizer work to reach a vaccine deal. ....
Firm faces supply issues but striving to meet goal - EU source J&J says it will begin deliveries to EU in second quarter J&J one-dose shot set to be approved in EU on March 11 BRUSSELS, March 9 (Reuters) - Johnson & Johnson has told the European Union it is facing supply issues that may complicate plans to deliver 55 million doses of its COVID-19 vaccine to the bloc in the second quarter of the year, an EU official told Reuters. Any delay would be a further blow to EU s vaccination plans, which have been hampered by bumpy supplies from other vaccine ....